We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Postprandial VLDL-TG Metabolism

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01961024
Recruitment Status : Completed
First Posted : October 11, 2013
Last Update Posted : May 3, 2017
Sponsor:
Information provided by (Responsible Party):
Esben Søndergaard, University of Aarhus

Brief Summary:
In thise study, we aim to determine the effect of meal fat on VLDL-TG kinetics in type 2 diabetic and healthy subjects matched for BMI in order to elucidate the potential pathophysiological differences in VLDL-TG FA channeling towards oxidation and storage in abdominal and leg subcutaneous adipose tissue. Specifically, we want to measure, by way of fat and muscle biopsies, the quantitative postprandial storage of VLDL-TG FA's in skeletal muscle and adipose tissue in relation to a series of tissue specific proteins and enzymes that might be involved in regulating skeletal muscle and adipose tissue FA storage.

Condition or disease
Type 2 Diabetes

Study Type : Observational
Actual Enrollment : 21 participants
Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Postprandial VLDL-TG Metabolism
Study Start Date : January 2014
Primary Completion Date : August 2015
Study Completion Date : August 2015

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Group/Cohort
Type 2 diabetic men
Age- and weight-matched controls



Primary Outcome Measures :
  1. VLDL-TG storage in adipose tissue [ Time Frame: 3 hours ]

Secondary Outcome Measures :
  1. 18F-THA fractional storage [ Time Frame: 6 Hours ]

Biospecimen Retention:   Samples With DNA
specimen of muscle specimen of adipose tissue


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   30 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Males with diabetes from the department´s out-patient clinic. Control group of healthy volunteers
Criteria

Inclusion Criteria:

  • Written consent

Exclusion Criteria:

  • Known diseases
  • Alcohol abuse
  • Smoker
  • Regular use of medicine

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01961024


Locations
Denmark
Department of Endocrinology MEA, Aarhus Hospital
Aarhus C, Please Select, Denmark, 8000
Sponsors and Collaborators
University of Aarhus

Responsible Party: Esben Søndergaard, Post Doc, MD, PhD, University of Aarhus
ClinicalTrials.gov Identifier: NCT01961024     History of Changes
Other Study ID Numbers: ES-0006
First Posted: October 11, 2013    Key Record Dates
Last Update Posted: May 3, 2017
Last Verified: May 2017

Keywords provided by Esben Søndergaard, University of Aarhus:
VLDL-TG kinetics
Postprandial state
Obesity